Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) CEO Purchases $616,700.00 in Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. purchased 35,000 shares of the business’s stock in a transaction dated Wednesday, April 29th. The shares were purchased at an average cost of $17.62 per share, with a total value of $616,700.00. Following the acquisition, the chief executive officer owned 1,786,039 shares in the company, valued at $31,470,007.18. This trade represents a 2.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Zenas BioPharma Stock Performance

Shares of Zenas BioPharma stock opened at $19.36 on Friday. The company has a 50 day moving average of $22.33 and a 200-day moving average of $27.09. Zenas BioPharma, Inc. has a 1-year low of $8.51 and a 1-year high of $44.60. The company has a current ratio of 5.61, a quick ratio of 5.61 and a debt-to-equity ratio of 0.32. The company has a market cap of $1.11 billion, a PE ratio of -2.48 and a beta of -0.61.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Monday, April 13th. The company reported ($1.10) earnings per share for the quarter. As a group, equities research analysts forecast that Zenas BioPharma, Inc. will post -4.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zenas BioPharma

Large investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in shares of Zenas BioPharma during the fourth quarter valued at $38,000. Quarry LP increased its holdings in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Zenas BioPharma in the third quarter worth approximately $30,000. CWM LLC increased its stake in Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Zenas BioPharma in the fourth quarter valued at $95,000.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $44.00 price objective on shares of Zenas BioPharma in a research note on Tuesday, March 17th. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price objective on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Guggenheim increased their price objective on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Wall Street Zen downgraded shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 21st. Finally, Morgan Stanley increased their target price on Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 17th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Zenas BioPharma has a consensus rating of “Hold” and an average price target of $44.14.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.